Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources.

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources.

Rev Gastroenterol Mex. 2018 Apr 12;:

Authors: Marciano S, Haddad L, Borzi SM, D'Amico C, Gaite LA, Aubone MV, Sirotinsky ME, Ratusnu N, Frola MS, Aparicio MC, Ríos B, Anselmo MN, Hansen R, De Filippi S, Dans CG, de Labra L, Peche MA, Strella TM, Ibáñez Duran M, García Rosales MB, Dirchwolf M, Galdame OA, Gadano AC

Abstract
AIMS: To estimate the proportion of patients who access to direct-acting antivirals agents (DAAs) for the treatment of hepatitisC in Argentina and to evaluate factors associated with failure to access to treatment.
METHODS: We performed a cross-sectional study of DAAs prescriptions written by centers participating in the telemedicine project ECHOTM-Hospital Italiano of Buenos Aires between January 2016 and February 2017.
RESULTS: A total of 143 consecutive prescriptions were evaluated; the global access was 70% (95% CI: 62%-77%). The only factor independently associated with failure to access to treatment was belonging to the public healthcare system [OR 4.98 (95% CI: 2.05- 12.09)] in comparison to belonging to private insurance or HMOs.
CONCLUSION: Patients with hepatitisC who belong to the public healthcare system are 4 times more likely to fail to access to treatment of hepatitisC than patients with private insurance or other kind of insurance.

PMID: 29656845 [PubMed - as supplied by publisher]